Every lot published · search any lot number before you order

Tirzepatide SURMOUNT-1: Reading the 72-Week Results

SURMOUNT-1 was a randomized trial of tirzepatide in 2,539 adults with obesity or qualifying overweight, without diabetes. After 72 weeks, average body weight was 15.0%, 19.5%, and 20.9% lower across the three assigned tirzepatide groups. The placebo group averaged a 3.1% reduction. Each figure is the mean for a study group.

The SURMOUNT-1 study. 2,539 adults. 72 weeks. Randomized and controlled.GLP LIFE SCIENCES · RESEARCH NOTESThe SURMOUNT-1 study2,539 adults72 weeksRandomized and controlled

What did the trial measure?

The study evaluated percentage change in body weight and the share of participants who reached at least a 5% reduction. The average describes the group as a whole. The threshold result tells you how often participants reached a defined change. Reading both can be more informative than relying on either measure alone.

What happened in the placebo group?

Placebo participants took part in the same trial setting, which included lifestyle guidance. Their mean reduction was 3.1% at the reported time point. This gives a point of comparison for changes that occurred without assignment to tirzepatide within the study. When reading an article about these results, look for the placebo figure alongside the active groups.

What safety outcomes matter?

Gastrointestinal events were the most common adverse events with tirzepatide in the trial. The investigators also reported how often people stopped treatment because of adverse events. For clinical questions about the approved medication, use the current prescribing information, which has a broader set of warnings and conditions of use than a single trial report.

How should these figures be compared with retatrutide studies?

Start by checking which population, follow-up duration and statistical approach each trial used. The SURMOUNT-1 result can explain what occurred in SURMOUNT-1. A separate placebo-controlled study of retatrutide cannot establish which compound performed better in a direct comparison.

Sources and further reading

SURMOUNT-1 peer-reviewed paper · SURMOUNT-1 trial registration · U.S. prescribing information for Zepbound

GLP Life Sciences research library